Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Shown for Austria
What do you need help with?
- Join a trialStudies open to new patients in your country, and abroad if you want.6 open in Austria · 271 worldwide
- Offer tissue or dataGive a sample or your health data to research.
- Get supportPatient groups, money and work, help for family.1 group in Austria
- Access and costGetting a treatment that is not on offer here, and who pays.
- Questions for your doctorReady lists to print or copy before your next visit.
- Don't pay for thisOffers with no proof in people, and what to check first.
Where treatment stands for Fatty liver disease (MASLD/MASH)
Four steps, from proven to unproven.
Approved in Austria
We do not have the list of medicines approved in Austria yet. Your doctor knows what is available here.
Being tested in people
6 open trials in Austria, 271 worldwide. See the trials
- 0 Phase 1
- 0 Phase 2
- 5 Phase 3
- 1 Other studies
Phase 1 – first tests in people, mainly for safety · Phase 2 – does it help? · Phase 3 – compared with the usual treatment.
Trials taking new patients now. Each trial counts once; one in two phases counts as the higher one.
- ALN-CIDEB (Phase 3)
- DR10624 Injection (Phase 3)
- Efimosfermin alfa (Phase 3)
- Efruxifermin (Phase 3)
Only in the lab or in animals
Of the 20 newest articles, 1 was in animals and 0 in the lab. See them
No proof it works
We have not checked claims for this disease yet. Check a post or a product
Latest research
The five newest articles. The label comes from the PubMed index: whether it was tested in people, in animals or only in the lab.
- Not labelled yetHealth-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study.Lancet Reg Health Eur · 2026-10-29
- Not labelled yetAuthor Reply to Letter to the Editor Regarding ''Beyond Awareness: A Qualitative Assessment of Barriers and Facilitators to Implementing Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) Care Pathways in Primary Care''.Gastro Hep Adv · 2026-09-21
- Not labelled yetHepatocyte UBE4A protects against MASLD and MASH by maintaining ER homeostasis via UBXN4 interaction.bioRxiv · 2026-10-13
- Not labelled yetRevisiting alpha-fetoprotein thresholds for hepatocellular carcinoma surveillance in the metabolic dysfunction-associated steatotic liver disease era: time for an evidence-based recalibration.J Gastrointest Oncol · 2026-10-16
- Not labelled yetNative T1 mapping radiomics for assessing FIB-4-associated fibrosis risk in metabolic dysfunction-associated steatotic liver disease.Quant Imaging Med Surg · 2026-10-19
Not labelled yet: PubMed has not indexed the article yet, so we do not guess.
All articles further down this pageSupport near you
Patient groups and help in Austria.
- Hepatitis Hilfe Österreich – Plattform Gesunde LeberNationwide non-profit patient organisation for all liver diseases, founded in 1999 by patients: counselling, information leaflets and support for patients and relatives.
- 1450 – Rund-um-die-Uhr-GesundheitsberatungAustria's nationwide 24/7 telephone health advice line: trained staff assess symptoms and guide callers to the appropriate care.
- Telefonseelsorge Österreich – Notruf 142Free, confidential 24/7 emotional support and crisis line for anyone in Austria, reachable on 142.
All supportOrganisations that can help, further down this page
Cure status
- ALN-CIDEBPhase 3 · NCT06836609 · NCT07854782 · NCT07631637
- DR10624 InjectionPhase 3 · NCT07024212 · NCT07693777
- Efimosfermin alfaPhase 3 · NCT07221227 · NCT07701993 · NCT07358546 · NCT07221188 · NCT07704892
- EfruxiferminPhase 3 · NCT06215716 · NCT06161571 · NCT06528314
- Encapsulated FMTPhase 3 · NCT06461208
- Estradiol patchPhase 3 · NCT04833140
- GODEXPhase 3 · NCT06152991
- HSK31679Phase 3 · NCT07581951
- HydrochloroquinePhase 3 · NCT07265297
- IBI362Phase 3 · NCT06884293 · NCT06937749
- IVA337Phase 3 · NCT04849728
- LAENNEC (Human Placenta Hydrolysate) IVPhase 3 · NCT06493799
- LAENNEC (Human Placenta Hydrolysate) SCPhase 3 · NCT06493799
- MGL-3196Phase 3 · NCT03900429
- Misocholic TabPhase 3 · NCT07833514
- PegozaferminPhase 3 · NCT06419374 · NCT06318169
- PemvidutidePhase 3 · NCT07795164
- ResmetiromPhase 3 · NCT05500222 · NCT07763015 · NCT07830758 · NCT07335601 · NCT07143968 · NCT04951219
- RetatrutidePhase 3 · NCT07165028
- SemaglutidePhase 3 · NCT03884075 · NCT06884293 · NCT06005012 · NCT07466017
- Silymarin (Silybum marianum)Phase 3 · NCT07833514
- Silymarin 420 mgPhase 3 · NCT07863648
- SurvodutidePhase 3 · NCT07850063 · NCT06632444 · NCT06632457
- TirzepatidePhase 3 · NCT06934642 · NCT07527910 · NCT07165028
- vitamin EPhase 3 · NCT07303803 · NCT07863648
- RoflumilastPhase 2/3 · NCT07900087
- RupatadinPhase 2/3 · NCT07900100
- Sequential treatment of bevacizumab combined with atezolizumab (sequential group)Phase 2/3 · NCT07285850
- Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)Phase 2/3 · NCT07285850
- 2% Fat Cow's MilkPhase 2 · NCT06133101
Closest to patients
- Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.Phase 2/3 trial: RupatadinFaculty of Medicine, Tanta University, Tanta, Egypt · Tanta, EgyptPhase 2/3Results expected 2027
- Misocholic Tablets for Non-Viral Elevated Liver EnzymesPhase 3 trial: Misocholic Tab, Silymarin (Silybum marianum)Hanoi Traditional Medicine General Hospital · Hanoi, VietnamPhase 3Results expected 2027
- Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease PatientsPhase 2/3 trial: RoflumilastFaculty of Medicine, Tanta University, Tanta, Egypt · Tanta, EgyptPhase 2/3Results expected 2027
Choose one to continue
Larger text, shorter lines, fewer blocks, no animation.
Who are you looking for?
Your choice only changes the wording and the order on this page. It stays in this browser.
If you are looking for a relative
Here you will find questions you can ask, help with difficult talks, organisations for carers and your relative's rights.
Questions for your relative's doctor
How do I talk to them about this?
You do not need the right words. Ask what your relative wants to know, and let them set the pace. These pages can help.
Support for you as a carer
Looking after someone is work too. These organisations help carers, and the list further down this page shows helplines by country.
Power of attorney and patient rights, by country
A doctor can share information and a relative can act only with the patient's consent or a legal authority. It is easier to arrange this early.
- Hungary: patient rights representatives (Integrált Jogvédelmi Szolgálat)
- Germany: power of attorney and care directives (Federal Ministry of Justice)
- Austria: adult protection and representation (Ministry of Justice)
- United Kingdom: lasting power of attorney (GOV.UK)
- EU: your rights to healthcare in another EU country (Your Europe)
If you are looking for your child
Children are often treated differently from adults, in specialist centres. Here is where to start.
Before you pay
Parents often receive offers of paid treatment. Please go through this list before you pay for anything.
For patient organisations
You can share or print these pages for your members. They are free and need no account.
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
New and changed trials of the last 30 days, without an account and without tracking.
RSS feedCalendar reminderPublication
Health-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study.
Health-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study.
The Lancet regional health. Europe
PubMed · PMID 42999578Publication
Native T1 mapping radiomics for assessing FIB-4-associated fibrosis risk in metabolic dysfunction-associated steatotic liver disease.
Native T1 mapping radiomics for assessing FIB-4-associated fibrosis risk in metabolic dysfunction-associated steatotic liver disease.
Quantitative imaging in medicine and surgery
PubMed · PMID 42997786Publication
Revisiting alpha-fetoprotein thresholds for hepatocellular carcinoma surveillance in the metabolic dysfunction-associated steatotic liver disease era: time for an evidence-based recalibration.
Revisiting alpha-fetoprotein thresholds for hepatocellular carcinoma surveillance in the metabolic dysfunction-associated steatotic liver disease era: time for an evidence-based recalibration.
Journal of gastrointestinal oncology
PubMed · PMID 42996869Publication
Superiority of magnetic resonance elastography and proton density fat fraction: an umbrella meta-analysis of non-invasive imaging for hepatic steatosis and fibrosis in metabolic dysfunction-associated steatotic liver disease and chronic hepatitis B.
Superiority of magnetic resonance elastography and proton density fat fraction: an umbrella meta-analysis of non-invasive imaging for hepatic steatosis and fibrosis in metabolic dysfunction-associated steatotic liver disease and chronic hepatitis B.
Quantitative imaging in medicine and surgery
PubMed · PMID 42997950Publication
Author Reply to Letter to the Editor Regarding ''Beyond Awareness: A Qualitative Assessment of Barriers and Facilitators to Implementing Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) Care Pathways in Primary Care''.
Author Reply to Letter to the Editor Regarding ''Beyond Awareness: A Qualitative Assessment of Barriers and Facilitators to Implementing Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) Care Pathways in Primary Care''.
Gastro hep advances
PubMed · PMID 42999568
Tools for your next step
Questions for your doctor
Pick up to 5 questions for your situation, then print them or take them on your phone.
Choose questionsOrganisations that can help
Helplines, patient groups and support services for you and your family.
Select your country to see the organisations there, starting with the ones closest to you.
Umbrella organisations (they connect national groups)
European Liver Patients' Association (ELPA)
European umbrella of national liver patient groups: liver disease information, HCC patient guide (with ESMO), clinical trial finder and liver cancer advocacy; points patients to member groups.
Visit site: European Liver Patients' Association (ELPA)
Global Liver Institute (GLI)
Global liver health advocacy body with a Liver Cancers Council, patient/caregiver education events and advocate training; not a direct support service.
Phone: +1 800 845 5910
Visit site: Global Liver Institute (GLI)
General support
For anyone who is ill, whatever the disease: patients' rights and legal aid, crisis lines, hospice and palliative care, care in another EU country, and patient organisations' umbrella bodies.
International
European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)
International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' Organizations
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Fatty liver disease (MASLD/MASH) work.
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
University of California San Diego
San Diego, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Virginia Commonwealth University
Richmond, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Chinese University of Hong Kong
Hong Kong, Hong Kong
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Fudan University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
National University of Singapore
Singapore, Singapore
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
Yonsei University
Seoul, South Korea
Team details appear once the team leader joins.
Is this your team? Claim it